ACADIA Pharmaceuticals

ACADIA Pharmaceuticals is a drug discovery and development company that efficiently identifies target-specific small molecule drug candidates using its proprietary chemical-genomics platform. ACADIA's uniquely productive platform integrates genomics, chemistry and biology to rapidly identify and validate drug targets and discover novel chemistries specific to those targets. ACADIA focus on major diseases that represent some of the largest pharmaceutical markets in the world, including psychosis, chronic pain, glaucoma and dementia. ACADIA's corporate headquarters as well as its genomics and biological research facilities are located in San Diego, California. ACADIA also maintains chemistry research facilities in Copenhagen, Denmark.

Contact Details: 3911 Sorrento Valley Boulevard San Diego 92121 United States of America Tel: +1 (858) 558-2871 Fax: +1 (858) 558-2872 Email: WWW: www.acadia-pharm.com/

Recent Publications by ACADIA Pharmaceuticals:
Synthesis, Structure-Activity Relationships, and Characterization of Novel Nonsteroidal and Selective Androgen Receptor Modulators. Herein we describe the discovery of ACP-105 (1), a novel and potent...	28th October, 2009	ACADIA Pharmaceuticals AB, Medeon Science Park, S-205 12 Malmo, Sweden.	J Med Chem. 2009 Oct 26. DOI Direct Link
AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. The recent discovery of allosteric potentiators and agonists of the...	20th October, 2009	ACADIA Pharmaceuticals Inc., 3911 Sorrento Valley Blvd., San Diego, CA	Neuropharmacology. 2009 Oct 14. DOI Direct Link
Discovery of selective nonpeptidergic neuropeptide FF2 receptor agonists. We report the discovery and initial characterization of a novel class of...	7th October, 2009	ACADIA Pharmaceuticals AB, Medeon Science Park, S-205 12 Malmo, Sweden.	J Med Chem. 2009 Nov 12;52(21):6511-4. DOI Direct Link
Discovery of non-peptidergic MrgX1 and MrgX2 receptor agonists and exploration of an initial SAR using solid-phase synthesis. A class of small molecules displaying comparable activities with peptide...	21st August, 2009	ACADIA Pharmaceuticals AB, Medeon Science Park, S-205 12 Malmo, Sweden.	Bioorg Med Chem Lett. 2009 Mar 15;19(6):1729-32. Epub 2009 Jan 30. DOI Direct Link
Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists. A novel class of CB1 inverse agonists was discovered. To efficiently...	29th April, 2009	ACADIA Pharmaceuticals AB, Malmo, Sweden.	J Med Chem. 2009 Apr 9;52(7):1975-82. DOI Direct Link
→View more ACADIA Pharmaceuticals research publications.

Press Releases on ACADIA Pharmaceuticals:
Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinson's Disease	22nd January, 2009	MediciGlobal	Study Recruiting Adult Parkinson's Patients with Behavioral Changes KING OF PRUSSIA, Pa., Jan. 22 /PRNewswire/ -- Parkinson's disease affects 6.3 million people worldwide. While the

BioNews Results for ACADIA Pharmaceuticals:
Acadia Pharmaceuticals Down 25.5% Since SmarTrend's Sell Recommendation	Individual.com:  Nov 13 2009 12:52AM Matching: acadia pharmaceuticals
Acadia Pharmaceuticals Down 25.5% Since SmarTrend's Sell Recommendation	TradingMarkets:  Nov 12 2009 7:05PM Matching: acadia pharmaceuticals
Acadia Pharmaceuticals Posts 3Q 2009 Financial Results	Individual.com:  Nov 12 2009 7:56AM Matching: acadia pharmaceuticals
ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results	SmartBrief:  Nov 11 2009 1:57AM Matching: acadia pharmaceuticals
ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results	Yahoo! Canada:  Nov 10 2009 4:09AM Matching: acadia pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more ACADIA Pharmaceuticals news.

ACADIA Pharmaceuticals Clinical Trials:
ACP-104 in Acutely Psychotic Subjects With Schizophrenia

ACADIA Pharmaceuticals Patents:
US Patent No.	Title
7601740	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
7300928	Benzimidazolidinone derivatives as muscarinic agents
7291611	Benzimidazolidinone derivatives as muscarinic agents
7273857	Benzimidazolidinone derivatives as muscarinic agents
7268232	Androgen receptor modulators and method of treating disease using the same
→View more ACADIA Pharmaceuticals patents.

ACADIA Pharmaceuticals (ACAD) Financial information Links from Barchart
ACAD Quote from from Barchart.com
ACAD Chart from from Barchart.com
ACAD Profile from from Barchart.com
ACAD Opinion from from Barchart.com
→View more ACADIA Pharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 1350 times since April 2007, the link to the organisation's website has been followed 218 times

Recent Search Terms used to find this page: acadia sweden address | Acadia Pharmaceuticals news | acadia pharmaceuticals | acadia pharmaceuticals | acadia pharmaceuticals ab | dibenzothiazepines class | A/S and A/B acadia inc | ACADIA Pharmaceuticals Inc. Corporate Headquarters 3911 Sorrento Valley Blvd. San Diego CA 92121 USA Tel 1 858 ... Fax 1 858 558-2872 | Discovery of non-peptidergic MrgX1 and MrgX2 receptor agonists and exploration of an initial SAR using solid-phase synthesis | acadia pharmaceuticals patents | .

Search for more companies in San Diego

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ACADIA Pharmaceuticals